Seven important updates from the ASCO Annual Meeting

This year’s ASCO Annual Meeting featured the theme “Collective wisdom: The future of patient-centered care and research.”

HemOnc Today recaps key developments from the meeting that reflect that theme, as well as other studies that attendees may have missed but could still have considerable impact on patient care.

Increased collaboration and a willingness to see beyond the expected will be critical to the success of the national cancer moonshot initiative, Vice President Joe Biden told ASCO Annual Meeting attendees. Read more
Brian J. Bolwell, MD, chairman of Taussig Cancer Institute at Cleveland Clinic, contends efforts to moderate prices for cancer drugs are “utterly imperative, both for the health care economy, as well as for our citizens.” Watch here
Treatment with T cells genetically modified to express chimeric antigen receptors targeting CD19 induced remission in patients with advanced B-cell lymphoma when administered with low-dose chemotherapy. Read more
Perioperative complications increased the 1-year risk for death after colon cancer surgery among patients of all ages. Read more
Extending aromatase inhibitor treatment with letrozole from 5 years to 10 years significantly improved DFS without compromising quality of life in postmenopausal women with early-stage breast cancer. Read more
Patients with progressive small cell lung cancer after previous therapy demonstrated delayed tumor growth and tumor shrinkage when treated with rovalpituzumab tesirine, according to results of a first-in-human study of the drug. Read more
CPX-351 prolonged OS and EFS in patients with high-risk secondary acute myeloid leukemia, according to phase 3 study results. Read more